You Position: Home > Paper

Docetaxel combined Nedaplatin in the treatment of advanced non-small cell lung cancer

( views:188, downloads:36 )
Author:
No author available
Journal Title:
China Clinical Practical Medicine
Issue:
2
DOI:
10.3760/cma.j.issn.1673-8799.2014.02.004
Key Word:
多西他赛;奈达铂;非小细胞肺癌;Docetaxel;Nedaplatin;non-small cell lung cancer

Abstract: ObjectiveTo study Docetaxel combined Nedaplatin treatment of advanced non-small cell lung cancer clinical curative effect and adverse reaction.Methods32 cases of non-small cell lung cancer patients were given Docetaxel, 75 mg/m2 and Nedaplatinm, 100 mg/m2 regimen for treatment. Every three weeks for a treatment cycle, and observe the clinical curative effect and adverse reaction occurred in two cycles .ResultsThe total effective treatment of 32 patients was 14/32, disease control rates of 25/32, mainly belong to Ⅰ - Ⅱ degree of adverse reaction, and a number of the reaction with leuk openia, nausea and vomiting and hair loss as the main adverse reaction.ConclusionDocetaxel combined Nedaplatin treatment of advanced non-small cell lung cancer with high disease control rates, and the adverse reaction to a lesser degree, characterized by the good tolerance and can be used for advancing non-small cell lung cancer chemotherapy regimens as the first choice.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn